FM
MACK

Family Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Family Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2,733
Closed -$88K – 79
2016
Q4 		$88K Buy
2,733
+572
+26% +$24.4K 0.06% 62
2016
Q3 		$108K Buy
2,161
+382
+21% +$15.9K 0.06% 74
2016
Q2 		$75K Buy
+1,779
New +$96.9K 0.04% 77
2016
Q1 		– Sell
-1,525
Closed -$95K – 85
2015
Q4 		$95K Sell
1,525
-254
-14% -$17.9K 0.05% 74
2015
Q3 		$119K Buy
+1,779
New +$145K 0.05% 90
2015
Q2 		– Sell
-2,606
Closed -$244K – 110
2015
Q1 		$244K Sell
2,606
-1,525
-37% -$130K 0.11% 74
2014
Q4 		$367K Buy
4,131
+1,653
+67% +$120K 0.17% 64
2014
Q3 		$171K Buy
2,478
+699
+39% +$37.4K 0.08% 86
2014
Q2 		$102K Hold
1,779
– – 0.05% 80
2014
Q1 		$71K Hold
1,779
– – 0.04% 73
2013
Q4 		$75K Buy
+1,779
New +$51.6K 0.04% 66

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Family Management's MACK Position: Q1 2017 in Review

Family Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2017, closing a stake of 2,733 shares — an estimated $88K sold.

Family Management first reported a position in MACK in Q4 2013 and held it in 11 quarters. The position peaked at $367K in Q4 2014. 116 funds tracked by Wall St. Rank hold MACK as of Q1 2017.

  • Family Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Family Management sold 2,733 Merrimack Pharmaceuticals, Inc. shares in Q1 2017, an estimated $88K.
  • Family Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2013 and held it in 11 quarters.
  • Family Management's Merrimack Pharmaceuticals, Inc. position peaked at $367K in Q4 2014.
  • 116 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2017.

Based on Family Management's 13F filing for Q1 2017, filed 15 May 2017.